Simple Summary Owing to the 40-year worldwide efforts for improving diagnosis and
therapy for acute myeloid leukemia (AML), the second most common type of leukemia in …

Venetoclax is a strongly effective B-cell lymphoma-2 inhibitor (BCL-2) with an ability to
selectively restore the apoptotic potential of cancerous cells. It has been proven that in …

During the past decade, the outcomes of pediatric patients with acute myeloid leukemia
(AML) have plateaued with 5‐year event‐free survival (EFS) and overall survival (OS) of …

Acute myeloid leukemia (AML) is the second most common hematologic malignancy in
children. The incidence of childhood AML is much lower than acute lymphoblastic leukemia …

Despite advances in the clinical management of childhood acute myeloid leukemia (AML)
during the last decades, outcome remains fatal in approximately one third of patients …

Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently
investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk …

Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific
driver alterations, many of which are underrepresented in the current classification schemas …

Genetic data are becoming increasingly essential in the management of hematological
neoplasms as shown by two classifications published in 2022: the 5th edition of the World …

Objectives This study aimed to evaluate the characteristics and outcomes of infant patients
with leukemia. Methods A retrospective analysis was conducted in a cohort of 39 patients …

Purpose Although outcomes of children with acute myeloid leukemia (AML) have improved
over the last decades, around one-third of patients relapse. Measurable (or minimal) …